Repurposing know-how for drug development: case studies from the Swiss Tropical and Public Health Institute (Publications)
of neglected tropical diseases and other infectious diseases of poverty, such as schistosomiasis, malaria and human African trypanosomiasis.
Synthesis and antiprotozoal activity of azabicyclo-nonane pyrimidine hybrids (Publications)
protozoan parasites. A series of fused hybrids were synthesized and tested in vitro against pathogens of malaria tropica and sleeping sickness. The activities and selectivities of compounds strongly depended on
The pharmacokinetics and drug-drug interactions of ivermectin in <em>Aedes aegypti</em> mosquitoes (Publications)
Mosquitoes are vectors of major diseases such as dengue fever and malaria. Mass drug administration of endectocides to humans and livestock is a promising complementary approach to current insecticide-based
Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of <em>Aotus nancymaae</em>, a non-human... (Publications)
to explore complex host-pathogen interactions in non-human primate animal models, particularly in malaria vaccine research
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents (Publications)
mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient
Evaluation of ethnobotanically selected Benin medicinal plants for their in vitro antiplasmodial activity (Publications)
Twenty extracts from nine Benin medicinal plants, traditionally used to treat malaria, were screened for in vitro antiplasmodial activity towards Plasmodium falciparum K1 chloroquine resistant and 3D7
Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy (Publications)
pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency,
Science Publication: SARS-CoV-2 Genomic Surveillance in Africa (Page)
https://www.swisstph.ch/fr/science-publication-sars-cov-2-genomic-surveillance-in-africa
set up the Baney Public Health Laboratory as part of the Equatoguinean Malaria Vaccine Initiative to work on the development of malaria vaccines. This laboratory was implemented as early as January 2020 by [...] Africa CDC, WHO AFRO and 300 other institutions across the continent, including Swiss TPH. From Malaria Vaccine Development to SARS-CoV-2 Screening Swiss TPH and partners from Equatorial Guinea contributed
Structure-activity relationship studies of pyrrolone antimalarial agents (Publications)
mammalian (L6) cells. Three representative compounds were selected for evaluation in a rodent model of malaria infection, and the best compound showed improved ability to decrease parasitaemia and a slight increase
Vector-borne diseases in humans and animals: activities of the Swiss Tropical Institut and risks for Switzerland (Publications)
This overview presents the Swiss Tropical Institute's (STI) activities on vector-borne diseases (malaria, trypanosomosis, and leishmaniosis in humans and tick-borne diseases in livestock), describes the
